Cavalcanti Suspended After Positive Drug TestCavalcanti Suspended After Positive Drug Test
Mixed martial arts stock photo: two man playing boxing
Photo by Hermes Rivera on Unsplash
Advertisement
MMAMMA News

Cavalcanti Suspended After Positive Drug Test

MMA News Staff
MMA Editorial Team ·

Igor Cavalcanti has been placed on temporary suspension after testing positive for 19-Norandrosterone following his 98-second knockout victory on Dana White's Contender Series in September, according to MMA Junkie.

The Brazilian middleweight earned a UFC contract when he stopped Oscar Ravello at the Meta Apex facility in Las Vegas on September 15. The Nevada State Athletic Commission administered the drug test that detected the banned substance.

Cavalcanti's Team Cites Medical Treatment for Knee Injury

Cavalcanti's manager Lucas Lutkus told MMA Junkie the nandrolone use stemmed from treatment for a torn medial meniscus and cartilage damage in his right knee. "According to his physician's medical report, he received three intramuscular injections of 25 mg between February 21 and March 7, 2026, to support muscle recovery and knee stability," Lutkus said. The 29-year-old was preparing for a fight in Europe at the time and had no knowledge he would compete in the UFC six months later.

Lutkus maintained that Cavalcanti disclosed his nandrolone use to the UFC and made no attempt to hide the treatment. All In Sports Management began representing the fighter in June, after the treatment had concluded. The team has gathered medical documentation and committed to full cooperation throughout the process.

Cavalcanti, who failed his first Contender Series attempt before returning to earn a contract, holds a 14-2 record with 11 knockouts. His UFC debut will remain on hold until NSAC schedules a hearing to evaluate his case.


Reported via:

  • MMA Mania — Dana White’s ‘Contender Series’ phenom who scored 98-second knockout fails UFC drug test, placed on suspension
Advertisement
Advertisement

Get Ringside Updates

Fight announcements, results, and analysis delivered to your inbox. No spam. Unsubscribe anytime.

Send me:

Join the discussion

Loading the discussion…